Medicenna Therapeutics Debt-to-Equity Ratio Growth & History (MDNAF)

Medicenna Therapeutics's debt-to-equity ratio was 0.05 for fiscal 2026.

View full Medicenna Therapeutics company overview

Medicenna Therapeutics annual debt-to-equity ratio history

Medicenna Therapeutics annual debt-to-equity ratio

Fiscal yearPeriod endedDebt-to-equity ratioChangeGrowth
20262026-03-310.050.04+444.95%
20252025-03-310.010.01
20242024-03-310.000.00
20232023-03-310.000.00
20222022-03-310.00−0.00
20212021-03-310.00−0.00−51.91%
20202020-03-310.00

Medicenna Therapeutics debt-to-equity ratio trends

Over the last five fiscal years, Medicenna Therapeutics's debt-to-equity ratio increased from 0.00 to 0.05, a change of 0.05. The latest reported quarter, Q1 2027, shows 0.06.

About the metric

What the debt-to-equity ratio means

The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.

Calculation and source

How debt-to-equity is calculated

TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Medicenna Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about MDNAF yet. Start the conversation.

Write the first post